Literature DB >> 21254353

Human teratogens: update 2010.

Lewis B Holmes1.   

Abstract

A wide variety of human teratogens have been identified. The characteristics of human teratogens can be used in the assessment of apparent "new" teratogens, when postulated. Information is available through online databases, such as TERIS and Reprotox, telephone-based counseling resources (e.g., Organization of Teratogen Information Systems [OTIS] and European Network Teratology Information Services [ENTIS]), reference books, annual meetings of the Teratology Society, and published articles. There are significant deficiencies in the information available: (1) lack of knowledge about the molecular and cellular basis for most teratogenic effects; (2) the inability to genetically identify more susceptible women before pregnancy; (3) little information is available on dermal and airborne exposures during pregnancy; and (4) most clinicians receive little, if any, training in the identification of or counseling for exposure to potential teratogens. There are many current dilemmas in counseling about exposures in pregnancy, including: (1) Is exposure to specific drugs, such as selected serotonin re-uptake inhibitors (SSRIs) and the inhibitors of tumor necrosis factor-alpha, teratogenic in the first trimester of pregnancy? (2) Are the increased risks of birth defects associated with assisted reproductive technology due, in part, to epigenetic effects? (3) What are the "safe" levels of exposure to the plasticizers phthalates during pregnancy? (4) How do we convince busy physicians, nurses, and pharmacists not to use the drug categories A, B, C, D, and X in counseling and to use more accurate sources? There is a need for a national advisory center for pregnancy registries to provide guidance when new registries are being developed.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254353     DOI: 10.1002/bdra.20748

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  7 in total

1.  Are epidemiological approaches suitable to study risk/preventive factors for human birth defects?

Authors:  Sonia Hernandez-Diaz; Anna Sara Oberg
Journal:  Curr Epidemiol Rep       Date:  2015-03

2.  Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Reza Boostani; Rosita Vakili; Samane Sadat Hosseiny; Ali Shoeibi; Bahare Fazeli; Mohammad Mehdi Etemadi; Faeze Sabet; Narges Valizade; Seyed Abdolrahim Rezaee
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

3.  Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy.

Authors:  Patricia Schlagenhauf; William A Blumentals; Pia Suter; Loredana Regep; Gabriel Vital-Durand; Martin T Schaerer; Margarita Suarez Boutros; Hans-Georg Rhein; Miriam Adamcova
Journal:  Clin Infect Dis       Date:  2012-04-10       Impact factor: 9.079

4.  Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials.

Authors:  Melba F Gomes; Vânia de la Fuente-Núñez; Abha Saxena; Annette C Kuesel
Journal:  Reprod Health       Date:  2017-12-14       Impact factor: 3.223

5.  Exposure of hospitalised pregnant women to plasticizers contained in medical devices.

Authors:  Cécile Marie; Sebti Hamlaoui; Lise Bernard; Daniel Bourdeaux; Valérie Sautou; Didier Lémery; Françoise Vendittelli; Marie-Pierre Sauvant-Rochat
Journal:  BMC Womens Health       Date:  2017-06-20       Impact factor: 2.809

6.  Maternal fever during pregnancy and offspring attention deficit hyperactivity disorder.

Authors:  Kristin Gustavson; Helga Ask; Eivind Ystrom; Camilla Stoltenberg; W Ian Lipkin; Pål Surén; Siri E Håberg; Per Magnus; Gun Peggy Knudsen; Espen Eilertsen; Michaeline Bresnahan; Heidi Aase; Siri Mjaaland; Ezra S Susser; Mady Hornig; Ted Reichborn-Kjennerud
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

7.  Use of medicines with unknown fetal risk among parturient women from the 2004 Pelotas Birth Cohort (Brazil).

Authors:  Andréa Dâmaso Bertoldi; Tatiane da Silva Dal Pizzol; Aline Lins Camargo; Aluísio J D Barros; Alicia Matijasevich; Iná S Santos
Journal:  J Pregnancy       Date:  2012-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.